GB0139 for COVID-19: real-time analysis

Download Image

Post

c19early.org

GB0139 for COVID-19

1 study with 41 patients

Serious outcome risk

GB0139

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 GB0139 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−40%

Mortality (1)−40%

RCTs (1)−40%

Late (1)−40%

00.511.5+

← GB0139
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jan 15 2023	Gaughan et al., American Journal of Respiratory and Critical Care Medicine, doi:10.1164/rccm.202203-0477OC	An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)
Jan 15 2023	40% higher mortality (p=0.7) and 100% longer hospitalization. RCT 41 hospitalized COVID-19 pneumonitis patients showing inhaled GB0139, a galectin-3 inhibitor, was well-tolerated with no treatment-related serious adverse events. There were greater rates of decline in inflammatory markers (CRP, LDH,..